



---

## **ASX Announcement and Media Release**

**14 December, 2017**

**SciGen Ltd**

### **ANNOUNCEMENT**

The Board of Directors of SciGen Limited (ASX: SIE) (“Company”) wishes to announce that the management of its holding company, Bioton S.A. (“Bioton”), has published the attached report on the Warsaw Stock Exchange on 13 December 2017 with regard to actions connected with the investment in a subsidiary – SciGen Ltd.

#### **About SciGen Limited**

SciGen Ltd (“SciGen”) is a biopharmaceutical company involved in sales and marketing of genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of endocrinology, paediatrics, neurology and oncology care.

Its core product portfolio consists of biosimilar products, notably, recombinant human insulin and recombinant human growth hormone which have undergone substantial clinical development. SciGen has since built a diversified portfolio in recent years, comprising neurology, oncology care products, paediatric supplements, orthopaedic injection therapy, anti-hypertensives and a range of medical devices.

SciGen has acquired the rights to distribute and market biopharmaceutical and proprietary products under both exclusive and semi-exclusive licensing arrangements. Its strategy is to focus on biosimilar products which have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen’s current focus is in the Asia Pacific region which provides growth opportunities for its range of products. Following a licensing agreement signed in early 2012, SciGen now has marketing rights for recombinant human insulin in the Middle East and Africa. SciGen’s contract manufacturer for recombinant human insulin is its ultimate holding company in Poland, Bioton S.A..

SciGen currently maintains internal sales and marketing teams at its subsidiary offices, whilst venturing into distribution partnerships in other markets. Through joint collaboration with its partners, SciGen uses its extensive expertise in regulatory and clinical environments, to cater to a broader spectrum of market.

SciGen was established in 1988, as a Singapore biopharmaceutical company. SciGen is listed on the Australian Stock Exchange (ASX code SIE). Its corporate headquarters is located in Singapore, with subsidiary offices in Australia, South Korea, China and a sales office in Philippines. Strategic distribution channels are present in Thailand, Hong Kong, Pakistan, Indonesia, Singapore, Bangladesh, Myanmar and Vietnam.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Adam Polonek SciGen Ltd +65 6779 6638

## **Taking a decision with regard to actions connected with the investment in a subsidiary – SciGen Ltd.**

With reference to the current report no 2017/38 dated December 12th, 2017, Bioton S.A. (the “Issuer“), in connection with obtainment of the Supervisory Board’s approval, on 12th December 2017 has taken a decision on commencement of actions regarding the further investment of the Issuer in a subsidiary company – SciGen Ltd. with its registered office in Singapore (the “SciGen”), aimed at securing an investor who will, in exchange for agreed consideration, acquire the Issuer’s investment in SciGen linked with acquisition by the Issuer from SciGen of the rights to the license allowing the trade of medicinal products in the form of recombinant human insulin and the acquisition of the “Scilin” trademarks. The commencement of actions was conditional upon the approval of the Supervisory Board of the Issuer.

The Issuer will publish to the public domain the further information related to the circumstances indicated in this report in accordance with legislation in force.